Editas Medicine, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 7, 2019 and accepted by EDGAR at Aug 7, 2019, 16:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $2.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $4.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $23.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $39.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$35.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$66.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$33.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$63.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.69 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$1.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$54.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $2.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $210.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $324.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $355.6m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $72.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $162.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $193.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-19-007470. Last ingested by Listed: Nov 6, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.